We have located links that may give you full text access.
Causal Effects of Circulating Lipids and Lipid-lowering Drugs on The Risk of Epilepsy: A Two-Sample Mendelian Randomization Study.
QJM : Monthly Journal of the Association of Physicians 2023 March 26
BACKGROUND: Previous studies have reported inconsistent results on the association between circulating lipids and lipid-lowering drugs with the risk of epilepsy.
OBJECTIVE: To assess whether genetically predicted circulating lipids and lipid-lowering drugs are causally associated with the risk of epilepsy outcome.
METHODS: We performed a two-sample Mendelian Randomization (MR) analysis model to genetically predict the causal effects of circulating lipids (Apolipoprotein A [APOA] Apolipoprotein B [APOB], Cholesterol, High density lipoprotein cholesterol [HDL-C], Low density lipoprotein cholesterol [LDL-C], Lipoprotein A, Triglycerides) and lipid-lowering drugs (HMG-CoA reductase [HMGCR] and Proprotein Convertase Subtilisin/Kexin Type 9 [PCSK9] inhibitors) on epilepsy. Nine MR analysis methods were conducted to analyze the final results. The inverse-variance weighted (IVW) method was used as the primary outcome. The other MR analysis methods (simple mode, weighted mode, simple median, weighted median, penalized weighted median, MR Egger, and MR-Egger [bootstrap)) were conducted as the complement to IVW. In addition, the robustness of the MR analysis results was assessed by leave-one-out analysis.
RESULTS: The IVW analysis method demonstrated that there is no causal association between circulating lipids (APOA: odds ratio [OR], 0.958, 95% confidence interval (CI), 0.728-1.261, P=0.760; APOB: OR, 1.092; 95% CI, 0.979-1.219, P=0.115; Cholesterol: OR, 1.210; 95% CI, 0.981-1.494, P=0.077; HDL-C: OR, 0.964; 95% CI, 0.767-1.212, P=0.753; LDL-C: OR, 1.100; 95% CI, 0.970-1.248, P=0.137; Lipoprotein A: OR, 1.082; 95% CI, 0.849-1.379, P=0.528; Triglycerides: OR, 1.126; 95% CI, 0.932-1.360, P=0.221) and lipid-lowering drugs (HMGCR inhibitors: OR, 0.221; 95% CI, 0.006-8.408, P=0.878; PCSK9 inhibitors: OR, 1.112; 95% CI, 0.215-5.761, P=0.902) with risk of epilepsy. The other MR analysis methods and further leave-one-out sensitivity analysis confirmed the robustness of final results.
CONCLUSION: This MR study demonstrated that there was no genetically predicted causal relationships between circulating lipids and lipid-lowering drugs with the risk of epilepsy.
OBJECTIVE: To assess whether genetically predicted circulating lipids and lipid-lowering drugs are causally associated with the risk of epilepsy outcome.
METHODS: We performed a two-sample Mendelian Randomization (MR) analysis model to genetically predict the causal effects of circulating lipids (Apolipoprotein A [APOA] Apolipoprotein B [APOB], Cholesterol, High density lipoprotein cholesterol [HDL-C], Low density lipoprotein cholesterol [LDL-C], Lipoprotein A, Triglycerides) and lipid-lowering drugs (HMG-CoA reductase [HMGCR] and Proprotein Convertase Subtilisin/Kexin Type 9 [PCSK9] inhibitors) on epilepsy. Nine MR analysis methods were conducted to analyze the final results. The inverse-variance weighted (IVW) method was used as the primary outcome. The other MR analysis methods (simple mode, weighted mode, simple median, weighted median, penalized weighted median, MR Egger, and MR-Egger [bootstrap)) were conducted as the complement to IVW. In addition, the robustness of the MR analysis results was assessed by leave-one-out analysis.
RESULTS: The IVW analysis method demonstrated that there is no causal association between circulating lipids (APOA: odds ratio [OR], 0.958, 95% confidence interval (CI), 0.728-1.261, P=0.760; APOB: OR, 1.092; 95% CI, 0.979-1.219, P=0.115; Cholesterol: OR, 1.210; 95% CI, 0.981-1.494, P=0.077; HDL-C: OR, 0.964; 95% CI, 0.767-1.212, P=0.753; LDL-C: OR, 1.100; 95% CI, 0.970-1.248, P=0.137; Lipoprotein A: OR, 1.082; 95% CI, 0.849-1.379, P=0.528; Triglycerides: OR, 1.126; 95% CI, 0.932-1.360, P=0.221) and lipid-lowering drugs (HMGCR inhibitors: OR, 0.221; 95% CI, 0.006-8.408, P=0.878; PCSK9 inhibitors: OR, 1.112; 95% CI, 0.215-5.761, P=0.902) with risk of epilepsy. The other MR analysis methods and further leave-one-out sensitivity analysis confirmed the robustness of final results.
CONCLUSION: This MR study demonstrated that there was no genetically predicted causal relationships between circulating lipids and lipid-lowering drugs with the risk of epilepsy.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app